Summary
In a randomised, double-blind, cross over trial, 25 patients with mild to moderate primary hypertension were given nifedipine 20–40 mg twice daily and labetalol 200–400 mg twice daily after a 4 week period on placebo, followed by the two drugs in combination. The BP during placebo therapy was 164/108 mmHg supine and 159/110 mmHg standing. After monotherapy with nifedipine for 6 weeks the supine BP was reduced by 18/13 mmHg and the standing BP by 20/12 mmHg; with labetalol the corresponding figures were 26/15 mmHg and 28/21 mmHg, respectively. The combined therapy induced a larger fall in BP, by 36/22 mmHg supine and by 39/24 mmHg standing; in 21 of 23 patients the BP became normal. The heart rate (HR) decreased during labetalol treatment alone and on the combined therapy. With nifedipine alone, the HR was unchanged in the supine position and increased on standing. Nifedipine increased plasma renin activity (PRA) and urinary aldosterone excretion (uA), whereas labetalol reduced both. During combination therapy, PRA and uA remained unchanged. There was a slight fall in HDL-cholesterol during treatment with labetalol alone and in combination with nifedipine. The fasting blood glucose increased slightly during treatment with each of the drugs, but neither caused a change in the concentrations of glycosylated haemoglobin A1, serum insulin, C-peptide, or plasma glucagon. Adverse effects as a rule were well tolerated and were related to the pharmacological effects of the drugs. Only 2 patients left the trial, both during labetalol treatment.
Similar content being viewed by others
References
Aoki K, Yoshida T, Kato S, Tazume K, Soto I, Takikawa K, Hotta K (1976) Hypotensive action and increased plasma renin activity by calcium antagonist (nifedipine) in hypertensive patients. Jap Heart J 17: 479–484
Bhatnagar SK, Amin MMA, Al-Yusuf AR (1984) Diabetogenic effects of nifedipine. Br Med J 289: 19
Brown RD, Swander A, McKenzie JK (1976) Urine aldosterone radioimmunoassay: validation of a method without chromatography. J Clin Endocrinol 42: 894–900
Bühler FR, Hulthén UL, Kiowski W, Bolli P (1982) Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients. Clin Sci 63 [Suppl 8]: 439s-442s
Charles S, Ketelslegers J-M, Buysschaert M, Lambert AE (1981) Hyperglycemic effect of nifedipine. Br Med J 283: 19–20
Corea L, Miele N, Bentivoglio M, Boschetti E, Agabiti-Rosei EI, Muiesan G (1979) Acute and chronic effects of nifedipine on plasma renin activity and plasma adrenaline and noradrenaline in controls and hypertensive patients. Clin Sci 57: 115s-117s
Ferrari A, Buccino N, DiRienzo M, Pedotti A, Mancia G, Zanchetti A (1981) Labetalol and 24-hour monitoring of arterial blood pressure in hypertensive patients. J Cardiovasc Pharmacol 3 [Suppl 1]: 542–552
Fray JCS (1980) Stimulus-secretion coupling of renin. Role of hemodynamic and other factors. Circ Res, 47: 485–492
Frick MH, Pörsti P (1976) Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension. Br Med J 272: 1046–1048
Fyhrquist F, Soveri P, Puutula L, Stenman UH (1976) Radioimmunoassay of plasma renin activity. Clin Chem 22: 250–256
Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varriecho M (1980) Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18: 395–398
Gomez G (1982) The effect of different antihypertensive therapies on plasma lipids. Practitioner 226: 985–991
Greenwood RH (1982) Hyperglycemic effect of nifedipine. Br Med J 284: 50
Guazzi MD, Fiorentini C, Olivari M, Bartorelli C, Necchi C, Polese A (1980) Short and long-term efficacy of a calcium antagonist agent (nifedipine) combined with methyldopa in the treatment of severe hypertension. Circulation 61: 913–919
Hansson L, Hähnel B (1976) Labetalol, a new alpha- and beta-adrenoceptor blocking agent, in hypertension. Br J Clin Pharmacol 3 [Suppl 3]: 763–764
Harrower ADB, Donnelly T (1981) Hyperglycemic effect of nifedipine. Br Med J 283: 796
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Hellman B (1975) The significance of calcium for glucose stimulation of insulin release. Endocrinology 97: 392–398
Holm G (1983) Adrenergic regulation of insulin release. Acta Med Scand 672 [Suppl]: 21–25
Hornung RS, Gould BA, Jones RJ, Sonecha TN, Raftery EB (1983) Nifedipine tablets for systemic hypertension: A study using continuous ambulatory intraarterial recording. Am J Cardiol 51: 1323–1327
Juhlin-Dannfelt A (1982) Metabolic effects of beta-adrenoceptor blockade on skeletal muscle at rest and during exercise. Acta Med Scand 665 [Suppl]: 113–115
Koch G (1979) Cardiovascular dynamics after acute and long term alpha- and beta-adrenoceptor blockade at rest, supine and standing, and during exercise. Br J Clin Pharmacol 8 [Suppl 2]: 101s-105s
Levy GP, Richards DA (1980) Labetalol. In: Scriabine A (ed) Pharmacology of antihypertensive drugs. Raven Press, New York, 325–347
Lund-Johansen P (1980) State of the art review. Hemodynamics in essential hypertension. Clin Sci 59: 343s-354s
McGonigle RJS, Williams L, Murphy MJ, Parsons V (1981) Labetalol and lipids. Lancet 1: 163
Opie LH, White DA (1980) Adverse interaction between nifedipine and beta-blockade. Br Med J 281: 1462–1463
Pedersen OL, Mikkelsen E (1978) Acute and chronic effects of nifedipine in arterial hypertension. Eur J Clin Pharmacol 14: 375–381
Pedersen OL, Mikkelsen E, Christensen NJ, Kornerup HJ, Pedersen EB (1979) Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol 15: 235–240
Prichard BNC, Boakes AJ (1976) Labetalol in long-term treatment of hypertension. Br J Clin Pharmacol 3 [Suppl 3]: 743–750
Rowland E, Evans T, Krikler D (1979) Effect of nifedipine on atrioventricular conduction as compared with verapamil. Br Heart J 42: 124–127
von Schenck H, Nilsson OR (1981) Radioimmunoassay of extracted glucagon compared with three non-extraction assays. Clin Chim Acta 109: 183–191
Thibonnier M, Bonnet F, Corvol P (1980) Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension. Eur J Clin Pharmacol 17: 161–164
Thulin T, Henningsen NC, Karlberg BE, Nilsson OR (1981) Clinical and metabolic effects of labetalol compared with atenolol in primary hypertension. Curr Ther Res 30: 194–204
Uusitupa M, Siitonen O, Härkönen M, Gordin A, Aro A, Hersio K, Johansson G, Korhonen T, Raurama R (1982) Metabolic and hormonal response to physical exercise during betal-selective and non-selective beta-blockade. Hormon Metab Res 14: 583–589
Valdès G, Soto ME, Croxatto H, Bellolio T, Corbalan R, Casanegra P (1982) Effects of nifedipine during low, normal and high intakes of sodium in patients with essential hypertension. Clin Sci 63 [Suppl 8]: 447s-450s
Wallin JD, O'Neil WM (1983) Labetalol — Current research and therapeutic status. Arch Intern Med 143: 485–490
Weidmann P, Chatel R, Ziegler WH, Flammer J, Reubi FC (1978) Alpha- and beta-adrenergic blockade with orally administered labetalol in hypertension. Am J Cardiol 41: 570–576
Zezulka AV, Gill JS, Beevers DG (1984) Diabetogenic effects of nifedipine. Br Med J 289: 437–38
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Öhman, K.P., Weiner, L., von Schenck, H. et al. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. Eur J Clin Pharmacol 29, 149–154 (1985). https://doi.org/10.1007/BF00547413
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00547413